ReviewFrontiers in pharmacology2026
The relevance of phenotypic definition in treatment resistant forms of major depressive disorder: a narrative review.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant depression (TRD) represents a major clinical and public health challenge contributing disproportionately to disability, healthcare utilisation, and societal costs. Progress in the field may be hindered by substantial heterogeneity in TRD phenotypic definitions and inconsistencies in their operationalisation across research and clinical settings. In this narrative review, we provide an updated overview of TRD research, focusing on limitations of current phenotypic frameworks, key sources of heterogeneity, and emerging biologically informed predictive approaches. We examine how variability in clinical assessment, comorbidities, treatment adherence, and adequacy of therapeutic trials may contribute to pseudo-resistance and consequent phenotypic instability, given that current TRD definitions largely rely on the number of failed antidepressant trials. Evidence on genetic, inflammatory, cognitive, and personality correlates of TRD is also summarised, highlighting both promising signals and persisting gaps. In addition, we discuss the potential role of measurement-based care and algorithm-guided treatment strategies in improving TRD identification and management. Overall, convergence toward more standardised TRD phenotyping-particularly through systematic assessment of adherence and symptom dimensions-appears essential to enhance ecological validity, support precision psychiatry, and advance translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.